Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Kelch-like ECH associated protein 1/Nuclear factor erythroid 2-like factor 2 (Keap1-Nrf2) signaling plays a pivotal role in response to oxidative stress in lung cancer.
|
30556750 |
2019 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
|
31416841 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nestin regulates cellular redox homeostasis in lung cancer through the Keap1-Nrf2 feedback loop.
|
31695040 |
2019 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To discover a small-molecule Keap1/Nrf2 pathway inhibitor, we conducted high-throughput screening in Keap1 mutant human lung cancer A549 cells using a transcriptional reporter assay.
|
30735010 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results confirm the effect of methylation on <i>KEAP1</i> transcription control across multiple histologies of lung cancer and suggest pyrosequencing as the best approach to investigate the pattern of CpGs methylation in the promoter region of <i>KEAP1.</i> The validation of this approach on lung cancer patient cohorts is mandatory to clarify the prognostic value of the epigenetic deregulation of <i>KEAP1</i> in lung tumors.
|
31159323 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
"Keaping" a lid on lung cancer: the Keap1-Nrf2 pathway.
|
30009666 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intriguingly, the signalling molecules perturbed by CCRK are divergent and cancer-specific, including the cell cycle regulators CDK2, cyclin D1, cyclin E and RB in glioblastoma, ovarian carcinoma and colorectal cancer, and KEAP1-NRF2 cytoprotective pathway in lung cancer.
|
29360538 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Resistance to gefitinib and cross-resistance to irreversible EGFR-TKIs mediated by disruption of the Keap1-Nrf2 pathway in human lung cancer cells.
|
29812969 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.
|
28145866 |
2017 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Further, CP alone or in combination with rapamycin strongly inhibited the in vitro and in vivo growth of tumors harboring mutations in KEAP1 or both KEAP1 and LKB1 that are frequently observed in lung cancer.
|
28504720 |
2017 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using a CRISPR-Cas9-based approach in a mouse model of KRAS-driven LUAD, we examined the effects of Keap1 loss in lung cancer progression.
|
28967920 |
2017 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our results suggest that CDK20 positively modulate the KEAP1-NRF2 cytoprotective pathway to regulate tumor progression and radiochemoresistance, implying that CDK20 is a novel, promising therapeutic target for lung cancer.
|
28534518 |
2017 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies revealed high-frequency alteration of Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-like factor 2 (Keap1/Nrf2) pathway within squamous lung cancer, attracting researchers to focus on this particular pathway.
|
26922479 |
2016 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knockdown (KD) of RSPO3, LGR4 or their signaling mediator IQGAP1 in lung cancer cell lines with Keap1 deficiency and high RSPO3-LGR4 expression led to reduction in cell proliferation and migration in vitro, and KD of LGR4 or IQGAP1 resulted in decrease in tumor growth and metastasis in vivo.
|
25531322 |
2015 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therapeutic strategies for lung cancer targeting NRF2 have observed mixed results, both anti- and protumorigenic effects; however, these differences seem to reflect the mutation status of NRF2 or KEAP1.
|
23577226 |
2013 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study indicates that targeting the interaction between AKT and TXNRD1 antioxidant pathways with MK2206 and auranofin, a U.S. Food and Drug Administration-approved drug, is a rational strategy to treat lung cancer and that KEAP1 mutation status may offer a predicative biomarker for such combination approaches.
|
23824739 |
2013 |
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
A possible gene silencing mechanism: hypermethylation of the Keap1 promoter abrogates binding of the transcription factor Sp1 in lung cancer cells.
|
23047008 |
2012 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic disruption of KEAP1/CUL3 E3 ubiquitin ligase complex components is a key mechanism of NF-kappaB pathway activation in lung cancer.
|
21795997 |
2011 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition identifying patients with KEAP1 genetic and epigenetic abnormalities may contribute to disease progression prediction and response to therapy in lung cancer patients.
|
21610322 |
2011 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Tumours from approximately 15% of patients with lung cancer harbour somatic mutations in KEAP1 that prevent effective NRF2 repression.
|
19321346 |
2009 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Nrf2 activation also stimulated growth of lung cancer-derived cell lines expressing KEAP1 at low levels and in mutant cell lines and in Keap1-null mouse embryonic fibroblasts under homeostatic conditions.
|
18316592 |
2008 |
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Thus, our results suggest for the first time that Keap1 expression is regulated by an epigenetic mechanism in lung cancer.
|
18555005 |
2008 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer.
|
16507366 |
2006 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we report a systematic analysis of the KEAP1 genomic locus in lung cancer patients and cell lines that revealed deletion, insertion, and missense mutations in functionally important domains of KEAP1 and a very high percentage of loss of heterozygosity at 19p13.2, suggesting that biallelic inactivation of KEAP1 in lung cancer is a common event.
|
17020408 |
2006 |